Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Small Cell Lung Cancer
Clinical trial register · China

Small Cell Lung Cancer Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19224 matching records held by the registry are in this view. Synced 11 Nov 2026, 03:17 UTC
19224
Studies in scope
all four open statuses
11811
Recruiting now
open to new participants
2030
Lead sponsors
across recruiting studies
Top sites
Beijing 18 Shanghai 16 Guangzhou 12 Fuzhou 11 Changsha 10
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd5 Amgen5 Merck Sharp & Dohme LLC2 Hangzhou DAC Biotechnology Co., Ltd.2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences2 China Medical University, China2 Sichuan Baili Pharmaceutical Co., Ltd.2 MediLink Therapeutics (Suzhou) Co., Ltd.2 Pfizer2 Hunan Cancer Hospital1 Peking University Cancer Hospital & Institute1 Qingdao Central Hospital1 CSPC Megalith Biopharmaceutical Co.,Ltd.1 Guangdong Association of Clinical Trials1 BeiGene1 AbbVie1 Zai Lab (Shanghai) Co., Ltd.1 Shanghai Pulmonary Hospital, Shanghai, China1 Tianjin First Central Hospital1 Hunan Province Tumor Hospital1 AstraZeneca1 Peking University First Hospital1 Tasly Biopharmaceuticals Co., Ltd.1 Fujian Medical University Union Hospital1 Innovent Biologics (Suzhou) Co. Ltd.1 Shanghai Public Health Clinical Center1 Sun Yat-sen University1 Heronova Pharmaceuticals1 Boehringer Ingelheim1 Sichuan University1 Peking Union Medical College Hospital1 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.1 Guangzhou Ruixin Biotechnological Co., LTD1 Ruijin Hospital1 Yunpeng Liu1 The Third Affiliated Hospital of Harbin Medical University1 Biokin (Shanghai) Biopharmaceutical Co., Ltd.1 Shanghai Henlius Biotech1 Daiichi Sankyo1 Tang-Du Hospital1 Shanghai Chest Hospital1 Akeso1 Anhui Provincial Hospital1
Site location
Beijing18 Shanghai16 Guangzhou12 Fuzhou11 Changsha10 Zhengzhou8 Chengdu6 Hangzhou6 Chongqing6 Nanchang5 Harbin4 Shenyang4 Wuhan4 Hefei4 Jinan3 Changchun3 Nanning3 Qingdao2 Xi'an2 Xiamen2 Tianjin2 Bengbu2 Quanzhou2 Cangzhou2 Chenzhou1 Hengyang1 Yueyang1 Nanjing1 Changchuan1 Naning1 Heilongjiang1 Shijiazhuang1 Yangzhou1 Shenzhen1 Guilin1 Guanzhou1 Weifang1 Jiamusi1 Fu'zhou1 Xinxiang1 Wuha1 Haerbin1 Jiangxi1 Beijin1 Longyan1 Zhangzhou1 Lanzhou1 Jiangmen1
All 48 locations
Target enrolment
to

Small Cell Lung Cancer trials in China

58 of 19224 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT07707895Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology, Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology
DrugsZL-1310·Obrixtamig·Atezolizumab
Boehringer Ingelheim
Phase 1/2
60
Nanning, Shanghai
2026-10-28
Recruiting
Amgen
Phase 3
400
Beijing, Shanghai
2026-08-28
Recruiting
Hangzhou DAC Biotechnology Co., Ltd.
Phase 1/2
200
Guangzhou
2026-08-19
Recruiting
NK Cells Plus ICI for SCLC Maintenance
NCT07759856Small Cell Lung Cancer
Tianjin First Central Hospital
Phase 2
42
Tianjin
2026-08
Recruiting
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
NCT07476287Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms
DrugPF-08634404
Pfizer
Phase 2
40
Beijing, Fuzhou, Zhengzhou, Wuhan, Nanchang, Shanghai, Hangzhou
2026-07-02
Not yet open
Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression
NCT07001995Small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer NSCLC
DrugsEtoposide and carboplatin·Limertinib
Hunan Province Tumor Hospital
Phase 2
30
Changsha
2026-05-01
Recruiting
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1
100
Shanghai
2026-04-21
Recruiting
A Study of DXC014 in Patients With Advanced Solid Tumors.
NCT07177937Small Cell Lung Cancer, Melanoma, Prostate Cancer, Other Advanced Solid Tumors
Hangzhou DAC Biotechnology Co., Ltd.
Phase 1
150
Beijing, Changsha, Nanchang, Qingdao, Hangzhou
2026-03-03
Recruiting
Shanghai Henlius Biotech
Phase 2
120
Hefei, Fu'zhou, Guangzhou, Nanning, Cangzhou, Harbin, Xinxiang, Wuha
2026-02-05
Not yet open
The Third Affiliated Hospital of Harbin Medical University
Phase 2
47
Harbin
2026-02-01
Recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
80
Guangzhou
2026-01-30
Recruiting
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3
420
Shanghai
2025-12-12
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 3
480
Hefei, Fuzhou, Xiamen, Guangzhou, Naning, Heilongjiang, Shijiazhuang, Zhengzhou
2025-11-30
Recruiting
AbbVie
Phase 2
180
Beijing, Zhengzhou, Wuhan, Nanchang, Shanghai, Chengdu
2025-11-25
Recruiting
A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
NCT07208773Advanced Solid Tumors, Non Small Cell Lung Cancer, Small Cell Lung Cancer
DrugsTam-Peli·Ivonescimab
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
260
Guangzhou
2025-10-29
Recruiting
68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer
NCT07508852SCLC, SCLC, Extensive Stage, SCLC, Limited Stage, Small Cell Lung Cancer
Peking University First Hospital
Phase 1/2
30
Beijing
2025-10-22
Recruiting
China Medical University, China
Phase 2
36
Shenyang
2025-10-15
Recruiting
ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
NCT07038096Small Cell Lung Cancer, Neuroendocrine Carcinoma
DrugsZG005·ZG006
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2
350
Guanzhou
2025-09-23
Active, closed
Amgen
Phase 3
350
Beijing, Quanzhou, Harbin, Jiamusi, Zhengzhou, Nanchang, Jinan, Shanghai
2025-08-18
Recruiting
Akeso
Phase 3
560
Beijing, Beijin, Chongqing, Fuzhou, Longyan, Zhangzhou, Lanzhou, Jiangmen
2025-06-13
Not yet open
Peking University Cancer Hospital & Institute
Phase 2
46
Beijing
2025-06-01
Active, closed
Amgen
Phase 1
29
Jinan, Chengdu, Fuzhou
2025-05-16
Not yet open
China Medical University, China
Phase 4
31
Shenyang
2025-04-30
Recruiting
A Study of SYS6040 for Injection in Patients With Advanced Solid Tumors
NCT06970795Small Cell Lung Cancer, Other Advanced Solid Tumors
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 1
180
Changchuan
2025-04-10
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
327
Beijing, Fuzhou, Nanjing, Shanghai, Chengdu, Hangzhou
2025-02-27
Recruiting
Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer
NCT06840704Non Small Cell Lung Cancer, Small Cell Lung Cancer
Hunan Cancer Hospital
Phase 3
121
Changsha, Chenzhou, Hengyang, Yueyang
2025-02-25
Recruiting
Sichuan University
Phase 2
80
Chengdu
2025-02-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
40
Beijing
2025-01-01
Recruiting
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1
190
Hefei, Fuzhou, Zhengzhou, Changsha, Nanchang, Jinan, Hangzhou
2024-12-30
Active, closed
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3
438
Guangzhou
2024-12-17
By invitation
Guangzhou Ruixin Biotechnological Co., LTD
Early Phase 1
10
Weifang
2024-12-15
Not yet open
A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
NCT06724263Recurrent Platinum-resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Cervical Cancers, Small Cell Lung Cancer
DrugB1962
Tasly Biopharmaceuticals Co., Ltd.
Phase 2
120
Shanghai
2024-12
Recruiting
Heronova Pharmaceuticals
Phase 1/2
60
Bengbu, Changsha
2024-09-11
Recruiting
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2
265
Shanghai
2024-09-02
Recruiting
Yunpeng Liu
Not applicable
38
Shenyang
2024-08-09
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
722
Guangzhou
2024-08-07
Recruiting
Biokin (Shanghai) Biopharmaceutical Co., Ltd.
Phase 1
115
Shanghai
2024-08-02
Recruiting
Anhui Provincial Hospital
Phase 1/2
45
Hefei
2024-07-01
Active, closed
Amgen
Phase 3
563
Beijing, Chongqing, Fuzhou, Quanzhou, Guangzhou, Guilin, Nanning, Cangzhou
2024-06-05
Recruiting
Daiichi Sankyo
Phase 3
540
Beijing, Changchun, Changsha, Chengdu, Chongqing, Haerbin, Hangzhou, Jiangxi
2024-05-21
Recruiting
Qingdao Central Hospital
Observational
70
Qingdao
2024-04-17
Recruiting
Peking Union Medical College Hospital
Phase 2
96
Beijing
2024-04-04
Recruiting
Tang-Du Hospital
Phase 4
24
Xi'an
2024-03-15
Active, closed
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
NCT06257264Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer
DrugsBGB-43395·Fulvestrant
BeiGene
Phase 1
103
Beijing, Guangzhou, Harbin, Changsha, Shenyang, Xi'an
2024-03-11
Active, closed
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 3
404
Beijing, Chongqing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Yangzhou
2024-02-20
Recruiting
Sun Yat-sen University
Phase 2
90
Guangzhou
2024-02-01
By invitation
Fujian Medical University Union Hospital
Phase 2
35
Fuzhou
2023-12-26
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
100
Changchun
2023-11-10
Recruiting
Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
NCT05978284Small Cell Lung Cancer, Neuroendocrine Carcinoma
DrugZG006
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2
54
Zhengzhou
2023-10-27
Recruiting
SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC
NCT06457906Small-cell Lung Cancer, Brain Metastases, SRS, Stereotactic Radiotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3
340
Beijing
2023-09-01
Active, closed
Guangdong Association of Clinical Trials
Phase 2
66
Guangzhou
2023-07-07
Recruiting
Ruijin Hospital
Not applicable
104
Shanghai
2021-01-30
Active, closed
Merck Sharp & Dohme LLC
Phase 3
672
Beijing, Chongqing, Fuzhou, Xiamen, Shenzhen, Zhengzhou, Wuhan, Changsha
2020-12-08
Active, closed
PF-07104091 as a Single Agent and in Combination Therapy
NCT04553133Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer
DrugsPF-07104091·Palbociclib·Letrozole·Fulvestrant
Pfizer
Phase 2
157
Shanghai, Tianjin
2020-09-16
Recruiting
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
40
Shanghai
2020-09-01
Active, closed
AstraZeneca
Phase 3
730
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou
2018-09-27
Recruiting
Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor
NCT03093688Non-small Cell Lung Cancer, Small Cell Lung Cancer, Pancreas Cancer, Hepatocellular Carcinoma
Shanghai Public Health Clinical Center
Phase 1/2
40
Shanghai
2017-03-01
Recruiting
Molecular Analysis and Treatment Options of SCLC
NCT05945745Small-cell Lung Cancer, Small Cell Lung Cancer, Combined Type, Small Cell Lung Carcinoma, Small Cell Lung Cancer Extensive Stage
Shanghai Chest Hospital
Observational
500
Shanghai
2016-01-01
Rows per page Showing 1–58 of 58
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 November 2026. https://priyalifescience.com/clinical-trials-china/condition/small-cell-lung-cancer

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,224 studies in total at the last sync on 11 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 58 of those studies listing the condition Small Cell Lung Cancer.

How many Small Cell Lung Cancer trials are recruiting in China?

39 of the 58 studies on this page are recruiting new participants as of the 11 Nov 2026, 03:17 UTC sync. A further 6 have not yet opened recruitment, 11 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Small Cell Lung Cancer), 58 studies
PhaseStudiesRecruitingShare
Phase 2181131%
Phase 314724.1%
Phase 1/2111019%
Phase 17512.1%
Observational335.2%
Not applicable223.4%
Phase 4213.4%
Early Phase 1101.7%

Most active sponsors

Lead sponsors with the most studies (Small Cell Lung Cancer)
Lead sponsorStudiesRecruiting
Amgen51
Suzhou Zelgen Biopharmaceuticals Co.,Ltd55
Cancer Institute and Hospital, Chinese Academy of Medical Sciences22
China Medical University, China21
Hangzhou DAC Biotechnology Co., Ltd.22
MediLink Therapeutics (Suzhou) Co., Ltd.21
Merck Sharp & Dohme LLC21
Pfizer21
Sichuan Baili Pharmaceutical Co., Ltd.21
AbbVie11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.